Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Infectivity Assessment of Recombinant Adeno-Associated Virus and Wild-Type Adeno-Associated Virus Exposed to Various Diluents and Environmental Conditions.

Tomono T, Hirai Y, Chono H, Mineno J, Ishii A, Onodera M, Tamaoka A, Okada T.

Hum Gene Ther Methods. 2019 Aug;30(4):137-143. doi: 10.1089/hgtb.2019.082.

PMID:
31317781
2.

Highly efficient genome editing for single-base substitutions using optimized ssODNs with Cas9-RNPs.

Okamoto S, Amaishi Y, Maki I, Enoki T, Mineno J.

Sci Rep. 2019 Mar 18;9(1):4811. doi: 10.1038/s41598-019-41121-4.

3.

Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen Receptor.

Uchibori R, Teruya T, Ido H, Ohmine K, Sehara Y, Urabe M, Mizukami H, Mineno J, Ozawa K.

Mol Ther Oncolytics. 2018 Dec 1;12:16-25. doi: 10.1016/j.omto.2018.11.003. eCollection 2019 Mar 29.

4.

Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9.

Tomono T, Hirai Y, Okada H, Miyagawa Y, Adachi K, Sakamoto S, Kawano Y, Chono H, Mineno J, Ishii A, Shimada T, Onodera M, Tamaoka A, Okada T.

Mol Ther Methods Clin Dev. 2018 Nov 1;11:180-190. doi: 10.1016/j.omtm.2018.10.015. eCollection 2018 Dec 14.

5.

Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H.

Blood. 2018 Sep 13;132(11):1134-1145. doi: 10.1182/blood-2017-08-802926. Epub 2018 Jul 25.

6.

Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer.

Ishikawa T, Okayama T, Sakamoto N, Ideno M, Oka K, Enoki T, Mineno J, Yoshida N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Konishi H, Kokura S, Uno K, Naito Y, Itoh Y.

Int J Cancer. 2018 Jun 15;142(12):2599-2609. doi: 10.1002/ijc.31285. Epub 2018 Feb 14.

7.

Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.

Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H.

Blood. 2017 Nov 2;130(18):1985-1994. doi: 10.1182/blood-2017-06-791202. Epub 2017 Aug 31.

PMID:
28860210
8.

Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome.

Wang L, Ma N, Okamoto S, Amaishi Y, Sato E, Seo N, Mineno J, Takesako K, Kato T, Shiku H.

Oncoimmunology. 2016 Jul 25;5(9):e1211218. eCollection 2016.

9.

A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy.

Casey NP, Fujiwara H, Tanimoto K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

PLoS One. 2016 Jun 7;11(6):e0156896. doi: 10.1371/journal.pone.0156896. eCollection 2016.

10.

Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.

Tanaka H, Fujiwara H, Ochi F, Tanimoto K, Casey N, Okamoto S, Mineno J, Kuzushima K, Shiku H, Sugiyama T, Barrett AJ, Yasukawa M.

Clin Cancer Res. 2016 Sep 1;22(17):4405-16. doi: 10.1158/1078-0432.CCR-15-2714. Epub 2016 Apr 18.

11.

Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantation.

Hashimoto H, Kitano S, Yamagata S, Miyagi Maeshima A, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Cytotherapy. 2015 Dec;17(12):1820-30. doi: 10.1016/j.jcyt.2015.08.005. Epub 2015 Oct 6.

PMID:
26452983
12.

Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.

Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Sci Rep. 2015 Oct 8;5:14896. doi: 10.1038/srep14896.

13.

Erratum to: Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S, Kim SW, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Int J Hematol. 2015 Oct;102(4):506. doi: 10.1007/s12185-015-1866-1. No abstract available.

PMID:
26362857
14.

Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer.

Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M, Sakai F, Kato A, Tanabe M, Enoki T, Mineno J, Naito Y, Itoh Y, Yoshikawa T.

J Transl Med. 2015 Aug 25;13:277. doi: 10.1186/s12967-015-0632-8.

15.

Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.

Fujiwara H, Ochi T, Ochi F, Miyazaki Y, Asai H, Narita M, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Leukemia. 2015 Dec;29(12):2393-401. doi: 10.1038/leu.2015.155. Epub 2015 Jun 24.

PMID:
26104661
16.

Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Int J Hematol. 2015 Jul;102(1):101-10. doi: 10.1007/s12185-015-1801-5. Epub 2015 May 7. Erratum in: Int J Hematol. 2015 Oct;102(4):506.

PMID:
25948083
17.

Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.

Otsu M, Yamada M, Nakajima S, Kida M, Maeyama Y, Hatano N, Toita N, Takezaki S, Okura Y, Kobayashi R, Matsumoto Y, Tatsuzawa O, Tsuchida F, Kato S, Kitagawa M, Mineno J, Hershfield MS, Bali P, Candotti F, Onodera M, Kawamura N, Sakiyama Y, Ariga T.

J Clin Immunol. 2015 May;35(4):384-98. doi: 10.1007/s10875-015-0157-1. Epub 2015 Apr 15.

PMID:
25875699
18.

Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer.

Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H.

Clin Cancer Res. 2015 May 15;21(10):2268-77. doi: 10.1158/1078-0432.CCR-14-1559. Epub 2015 Apr 8.

19.

Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.

Ishihara M, Seo N, Mitsui J, Muraoka D, Tanaka M, Mineno J, Ikeda H, Shiku H.

PLoS One. 2014 Aug 8;9(8):e104669. doi: 10.1371/journal.pone.0104669. eCollection 2014.

20.

CD4(+) T Cells Modified by the Endoribonuclease MazF Are Safe and Can Persist in SHIV-infected Rhesus Macaques.

Saito N, Chono H, Shibata H, Ageyama N, Yasutomi Y, Mineno J.

Mol Ther Nucleic Acids. 2014 Jun 10;3:e168. doi: 10.1038/mtna.2014.20.

21.

Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy.

Ochi F, Fujiwara H, Tanimoto K, Asai H, Miyazaki Y, Okamoto S, Mineno J, Kuzushima K, Shiku H, Barrett J, Ishii E, Yasukawa M.

Cancer Immunol Res. 2014 Mar;2(3):249-62. doi: 10.1158/2326-6066.CIR-13-0099-T. Epub 2014 Jan 3.

22.

Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8⁺ T cells.

Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y, Yamane M, Ueno H, Ideno M, Nukaya I, Enoki T, Mineno J, Takesako K, Hirano S, Shiku H.

Eur J Immunol. 2014 Jun;44(6):1747-58. doi: 10.1002/eji.201343969. Epub 2014 May 11.

23.

Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.

Ishikawa T, Kokura S, Enoki T, Sakamoto N, Okayama T, Ideno M, Mineno J, Uno K, Yoshida N, Kamada K, Katada K, Uchiyama K, Handa O, Takagi T, Konishi H, Yagi N, Naito Y, Itoh Y, Yoshikawa T.

PLoS One. 2014 Jan 31;9(1):e83786. doi: 10.1371/journal.pone.0083786. eCollection 2014.

24.

An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking.

Dodo K, Chono H, Saito N, Tanaka Y, Tahara K, Nukaya I, Mineno J.

PLoS One. 2014 Jan 15;9(1):e86275. doi: 10.1371/journal.pone.0086275. eCollection 2014.

25.

Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury.

Asai H, Fujiwara H, Kitazawa S, Kobayashi N, Ochi T, Miyazaki Y, Ochi F, Akatsuka Y, Okamoto S, Mineno J, Kuzushima K, Ikeda H, Shiku H, Yasukawa M.

J Hematol Oncol. 2014 Jan 6;7:3. doi: 10.1186/1756-8722-7-3.

26.

CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.

Tsukahara T, Ohmine K, Yamamoto C, Uchibori R, Ido H, Teruya T, Urabe M, Mizukami H, Kume A, Nakamura M, Mineno J, Takesako K, Riviere I, Sadelain M, Brentjens R, Ozawa K.

Biochem Biophys Res Commun. 2013 Aug 16;438(1):84-9. doi: 10.1016/j.bbrc.2013.07.030. Epub 2013 Jul 17.

27.

Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.

Miyazaki Y, Fujiwara H, Asai H, Ochi F, Ochi T, Azuma T, Ishida T, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Blood. 2013 Jun 13;121(24):4894-901. doi: 10.1182/blood-2012-11-465971. Epub 2013 May 2.

PMID:
23641014
28.

Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.

Iwami K, Natsume A, Ohno M, Ikeda H, Mineno J, Nukaya I, Okamoto S, Fujiwara H, Yasukawa M, Shiku H, Wakabayashi T.

Neuro Oncol. 2013 Jun;15(6):747-58. doi: 10.1093/neuonc/not007. Epub 2013 Mar 3.

29.

Sustained inhibition of HIV-1 replication by conditional expression of the E. coli-derived endoribonuclease MazF in CD4+ T cells.

Okamoto M, Chono H, Kawano Y, Saito N, Tsuda H, Inoue K, Kato I, Mineno J, Baba M.

Hum Gene Ther Methods. 2013 Apr;24(2):94-103. doi: 10.1089/hgtb.2012.131. Epub 2013 Mar 28.

PMID:
23442049
30.

Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.

Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Inoue H, Yasukawa M.

PLoS One. 2013;8(2):e56820. doi: 10.1371/journal.pone.0056820. Epub 2013 Feb 18.

31.

Manipulation of human early T lymphopoiesis by coculture on human bone marrow stromal cells: potential utility for adoptive immunotherapy.

Liu B, Ohishi K, Orito Y, Nakamori Y, Nishikawa H, Ino K, Suzuki K, Matsumoto T, Masuya M, Hamada H, Mineno J, Ono R, Nosaka T, Shiku H, Katayama N.

Exp Hematol. 2013 Apr;41(4):367-76.e1. doi: 10.1016/j.exphem.2012.12.001. Epub 2012 Dec 17.

PMID:
23257689
32.

A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression.

Okamoto S, Amaishi Y, Goto Y, Ikeda H, Fujiwara H, Kuzushima K, Yasukawa M, Shiku H, Mineno J.

Mol Ther Nucleic Acids. 2012 Dec 18;1:e63. doi: 10.1038/mtna.2012.52.

33.

HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system.

Kanda T, Ochi T, Fujiwara H, Yasukawa M, Okamoto S, Mineno J, Kuzushima K, Tsurumi T.

Cancer Gene Ther. 2012 Aug;19(8):566-71. doi: 10.1038/cgt.2012.34. Epub 2012 Jun 22.

PMID:
22722376
34.

siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions.

Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, Shiku H.

Gene Ther. 2012 Oct;19(10):959-66. doi: 10.1038/gt.2011.185. Epub 2011 Nov 24.

PMID:
22113316
35.

Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity.

Nagai K, Ochi T, Fujiwara H, An J, Shirakata T, Mineno J, Kuzushima K, Shiku H, Melenhorst JJ, Gostick E, Price DA, Ishii E, Yasukawa M.

Blood. 2012 Jan 12;119(2):368-76. doi: 10.1182/blood-2011-06-360354. Epub 2011 Oct 24.

PMID:
22025529
36.

T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.

Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, Ito M, Nukaya I, Mineno J, Takesako K, Ikeda H, Shiku H.

Cancer Sci. 2012 Jan;103(1):17-25. doi: 10.1111/j.1349-7006.2011.02111.x. Epub 2011 Nov 8.

37.

In vivo safety and persistence of endoribonuclease gene-transduced CD4+ T cells in cynomolgus macaques for HIV-1 gene therapy model.

Chono H, Saito N, Tsuda H, Shibata H, Ageyama N, Terao K, Yasutomi Y, Mineno J, Kato I.

PLoS One. 2011;6(8):e23585. doi: 10.1371/journal.pone.0023585. Epub 2011 Aug 17.

38.

Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Blood. 2011 Aug 11;118(6):1495-503. doi: 10.1182/blood-2011-02-337089. Epub 2011 Jun 14.

PMID:
21673345
39.

Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.

Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, Mineno J, Shiku H, Nishida S, Sugiyama H, Tajiri H, Homma S.

Cancer Immunol Immunother. 2011 Sep;60(9):1289-97. doi: 10.1007/s00262-011-1033-3. Epub 2011 May 24.

PMID:
21607557
40.

Feasibility of gene-immunotherapy using WT1-specific T-cell receptor gene transfer for infant acute lymphoblastic leukemia with MLL gene rearrangement.

Nagai K, Fujiwara H, Ochi T, Okamoto S, Mineno J, Shiku H, Koh K, Sugita K, Ishii E, Yasukawa M.

Blood Cancer J. 2011 Mar;1(3):e10. doi: 10.1038/bcj.2011.8. Epub 2011 Mar 18. No abstract available.

41.

Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis.

An J, Fujiwara H, Suemori K, Niiya T, Azuma T, Tanimoto K, Ochi T, Akatsuka Y, Mineno J, Ozawa H, Ishikawa F, Kuzushima K, Yasukawa M.

Int J Hematol. 2011 Feb;93(2):176-185. doi: 10.1007/s12185-010-0758-7. Epub 2011 Jan 13.

PMID:
21229399
42.

[Adoptive immunotherapy for cancer with genetically engineered T cells].

Ikeda H, Okamoto S, Mineno J, Imai N, Ito M, Yasukawa M, Takesako K, Shiku H.

Rinsho Ketsueki. 2010 Nov;51(11):1647-53. Review. Japanese. No abstract available.

PMID:
21157127
43.

Optimization of lentiviral vector transduction into peripheral blood mononuclear cells in combination with the fibronectin fragment CH-296 stimulation.

Chono H, Goto Y, Yamakawa S, Tanaka S, Tosaka Y, Nukaya I, Mineno J.

J Biochem. 2011 Mar;149(3):285-92. doi: 10.1093/jb/mvq135. Epub 2010 Nov 23.

PMID:
21106541
44.

Acquisition of HIV-1 resistance in T lymphocytes using an ACA-specific E. coli mRNA interferase.

Chono H, Matsumoto K, Tsuda H, Saito N, Lee K, Kim S, Shibata H, Ageyama N, Terao K, Yasutomi Y, Mineno J, Kim S, Inouye M, Kato I.

Hum Gene Ther. 2011 Jan;22(1):35-43. doi: 10.1089/hum.2010.001. Epub 2010 Dec 12.

PMID:
20649483
45.

Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H, Kato I.

Cancer Res. 2009 Dec 1;69(23):9003-11. doi: 10.1158/0008-5472.CAN-09-1450. Epub 2009 Nov 10.

46.

Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.

Hiasa A, Nishikawa H, Hirayama M, Kitano S, Okamoto S, Chono H, Yu SS, Mineno J, Tanaka Y, Minato N, Kato I, Shiku H.

Gene Ther. 2009 May;16(5):620-8. doi: 10.1038/gt.2009.6. Epub 2009 Feb 26.

PMID:
19242528
47.

In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method.

Yu SS, Nukaya I, Enoki T, Chatani E, Kato A, Goto Y, Dan K, Sasaki M, Tomita K, Tanabe M, Chono H, Mineno J, Kato I.

Cancer Gene Ther. 2008 Aug;15(8):508-16. doi: 10.1038/cgt.2008.21. Epub 2008 May 9.

PMID:
18464805
48.

Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.

Hiasa A, Hirayama M, Nishikawa H, Kitano S, Nukaya I, Yu SS, Mineno J, Kato I, Shiku H.

Gene Ther. 2008 May;15(9):695-9. doi: 10.1038/sj.gt.3303099. Epub 2008 Feb 21.

PMID:
18288212
49.

Transient gene expression mediated by integrase-defective retroviral vectors.

Yu SS, Dan K, Chono H, Chatani E, Mineno J, Kato I.

Biochem Biophys Res Commun. 2008 Apr 18;368(4):942-7. doi: 10.1016/j.bbrc.2008.02.012. Epub 2008 Feb 13.

PMID:
18279658
50.

The expression profile of microRNAs in mouse embryos.

Mineno J, Okamoto S, Ando T, Sato M, Chono H, Izu H, Takayama M, Asada K, Mirochnitchenko O, Inouye M, Kato I.

Nucleic Acids Res. 2006 Mar 31;34(6):1765-71. Print 2006.

Supplemental Content

Loading ...
Support Center